A Randomized Phase 2 Trial to Assess the Efficacy of AT in Comparison to TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer : Evaluating the Homologous Recombination Deficiency(HRD) Biomarker
Overview
- Phase
- Phase 2
- Intervention
- AT regimen
- Conditions
- HER2-negative Breast Cancer
- Sponsor
- Sichuan Provincial People's Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Complete pathological response of breast and lymph nodes (ypT0/is ypN0; defined as no microscopic evidence of residual invasive viable tumor cells in all resected specimens of the breast and axilla)
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a prospective, randomized and open-label phase II study, evaluating the efficacy and safety of AT vs TP regimen as neoadjuvant treatment for early HER2-negative breast cancer. Participants will undergo/receive HRD testing after enrollment. HRD-positive patients will be randomly assigned in a ratio of 1:1 to receive AT（Doxorubicin or Epirubicin+docetaxel）or TP（Albumin paclitaxel + Cisplatin or Carboplatin）regimen respectively, followed by surgery. HRD-negative patients will be assigned to receive TP（Albumin paclitaxel + Cisplatin or Carboplatin）regimen if TNBC, or AT（Doxorubicin or Epirubicin+docetaxel）rigemen, followed by surgery.
Detailed Description
This study intends to adopt Simon's two-stage optimal design. In stage 1, 15 HRD-positive and 15 HRD-negative patients will be recruited to receive AT or TP regimen as neoadjuvant therapy. If more than 5 patients in the HRD-positive group achieve pCR(pathological complete response) , the trial expands to stage 2, otherwise the trial terminates. In stage 2, another 31 HRD- positive and 31 HRD-negative patients will be enrolled.
Investigators
Luojing
Prof.
Sichuan Provincial People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Written informed consent for all study specific procedures according to local regulatory requirements prior to beginning specific protocol procedures.
- •Age ≥ 18 years.
- •Male or female patients
- •ECOG performance status ≤1
- •Histologically confirmed invasive breast cancer by core needle or incisional biopsy (excisional biopsy is not allowed). Clinical stage T2-3 N0-2 or T1 N1-2 by physical exam or radiologic studies. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.
- •Centrally confirmed negative HER2-status. Centrally confirmed estrogen and progesterone receptor, and Ki-67 status detected on core biopsy. ER/PR positive is defined as ≥1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridisation (ISH) ratio ≥2.
- •Provide Formalin-fixed, paraffin-embedded (FFPE) breast tissue to take Homologous Recombinant Deficiency test.
- •Tumor lesion in the breast with a palpable size of \> 2 cm or a sonographical size of \>1 cm in maximum diameter. If the tumor is not detectable with sonography mammography assessment can be considered. The lesion has to be measurable in two dimensions, preferably by sonography. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.
- •Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results must be above the normal limit of the institution.
- •Laboratory requirements:
Exclusion Criteria
- •Prior chemotherapy for any malignancy within 3 years.
- •Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapy.
- •Ongoing use of any other investigational or study agents.
- •Previous malignant disease without being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).
- •Renal dysfunction for which exposure to cisplatin would be unsafe or require cisplatin dose modification (i.e., Cre \> 1.5 mg/dl or GFR \< 60 cc/min).
- •Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based chemotherapy).
- •Evidence of metastasis before randomization
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases, active or symptomatic viral hepatitis or chronic liver disease
- •Known history of heart disease, for example: myocardial infarction or symptomatic cardiac ischemia within 24 weeks before screening; congestive heart failure; randomized history of clinically significant ventricular arrhythmias within the previous year; Mobitz II level 2 Or a history of tertiary heart block, hypertension is uncontrolled
- •History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent.
Arms & Interventions
Arm a(HR+/HER2-,HRD-）
Participants receive AT regimen for neoadjuvant therapy
Intervention: AT regimen
Arm b(TNBC, HRD-)
Participants receive TP regimen for neoadjuvant therapy
Intervention: TP regimen
Arm c(HER2-,HRD+)
Participants receive AT regimen for neoadjuvant therapy
Intervention: AT regimen
Arm d(HER2-, HRD+)
Participants receive TP regimen for neoadjuvant therapy
Intervention: TP regimen
Outcomes
Primary Outcomes
Complete pathological response of breast and lymph nodes (ypT0/is ypN0; defined as no microscopic evidence of residual invasive viable tumor cells in all resected specimens of the breast and axilla)
Time Frame: 24 weeks
1. To compare the pathologic response to neoadjuvant AT regimen in HER2- breast cancer with and without HR-deficiency, defined as a high HRD score or a BRCA mutation 2. To compare the pathologic response to neoadjuvant TP regimen in HER2- breast cancer with and without HR-deficiency, defined as a high HRD score or a BRCA mutation 3. To compare the pathologic response to neoadjuvant AT vs TP regimen in HER2- breast cancer with HR-deficiency, defined as a high HRD score or a BRCA mutation
Secondary Outcomes
- Imaging response(24 weeks)
- Residual cancer burden in patients with HRD(up to 24 weeks)
- response by pCR in HRD high versus tBRCA(24 weeks)